Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results  ●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year  ●2021 Full Year Net Loss Improved $11.5 Million vs Prior...

Interpace Biosciences Announces Acceptance for Trading on the OTCQX PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today...

Interpace Biosciences Announces Path Forward in Letter to Shareholders PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to...

Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial Results on Wednesday, April 22, 2020 PARSIPPANY, NJ, April 22, 2020 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company...

Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019 PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET....